Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions

References

• Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, Bunin DI, Blakely EA, Bjornstad KA, Rosen CJ, Shuh DK, Raymond KN. 2010. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys 99:401–407.
   PubMed Web of Science ®Google Scholar
• Abergel RJ, Raymond KN. 2011. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators. Hemoglobin 35:276–290.
   PubMed Web of Science ®Google Scholar
• Ansoborlo E, Prat O, Moisy P, Den Auwer C, Guilbaud P, Carriere M, Gouget B, Duffield J, Doizi D, Vercouter T, Moulin C, Moulin V. 2006. Actinide speciation in relation to biological processes. Biochimie 88:1605–1618.
   PubMed Web of Science ®Google Scholar
• Bergeron RJ, Wiegand J, Singh S. 2009. Desferrithiocin analogue uranium decorporation agents. Int J Radiat Biol 85:348–361.
   PubMed Web of Science ®Google Scholar
• Bunn M, Heinonen O. 2011. Nuclear safety. Preventing the next Fukushima. Science 333:1580–1581.
   PubMed Web of Science ®Google Scholar
• Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. 2008. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiat Res 170:540–548.
   PubMed Web of Science ®Google Scholar
• Duffield J, Taylor DM. 1987. A spectroscopic study on the binding of plutonium(IV) and its chemical analogues to transferrin. Inorg Chim Acta 140:365–367.
   Web of Science ®Google Scholar
• Durbin PW. (2006). Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, eds. The Chemistry of the Actinide and Transactinide Elements. Netherlands: Springer.
   Google Scholar
• Durbin PW. 2008. Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators. Health Phys 95:465–492.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Jeung N, Kullgren B, Clemons GK. 1992. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 63:427–442.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Kullgren B, Xu J, Raymond KN. 1994. In vivo chelation of Am(III), Pu(IV), Np(V), and U(VI) in mice by tren(Me-3,2-HOPO). Radiat Prot Dosim 53:305–309.
   Web of Science ®Google Scholar
• Durbin PW, Kullgren B, Xu J, Raymond KN. 2000. Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. Int J Radiat Biol 76:199–214.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Kullgren B, Xu J, Raymond KN, Allen PG, Bucher JJ, Edelstein NM, Shuh DK. 1998. 237Np: oxidation state in vivo and chelation by multidentate catecholate and hydroxypyridinonate ligands. Health Phys 75:34–50.
   PubMed Web of Science ®Google Scholar
• Fukuda S. 2005. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Curr Med Chem 12:2765–2770.
   PubMed Web of Science ®Google Scholar
• Gorden AE, Shuh DK, Tiedemann BE, Wilson RE, Xu J, Raymond KN. 2005. Sequestered plutonium: [Pu(IV){5LIO(Me-3,2-HOPO)}2]–the first structurally characterized plutonium hydroxypyridonate complex. Chemistry 11:2842–2848.
   PubMed Web of Science ®Google Scholar
• ICRP. 1993. Annals of the ICRP. Volume 23. 3–4. Age-dependent doses to members of the public from intake of radionuclides: Part 2. Ingestion dose coefficients.
   Google Scholar
• ICRP. 1995. Annals of the ICRP. Volume 25. No. 1. Age-dependent doses to members of the public from intake of radionuclides: Part 3. Ingestion dose coefficients.
   Google Scholar
• Martell AE, Smith RM, Motekaitis RJ. 2004. NIST standard reference database 46.
   Google Scholar
• Miller C, Cubbage A, Dorman D, Grobe J, Holahan G, Sanfilippo N. 2011. Recommendations for enhancing reactor safety in the 21st century. U.S. Nuclear Regulatory Commission.
   Google Scholar
• Moore EG, Xu J, Dodani SC, Jocher CJ, D’Aléo A, Seitz M, Raymond KN. 2010. 1-Methyl-3-hydroxy-pyridin-2-one complexes of near infra-red emitting lanthanides: efficient sensitization of Yb(III) and Nd(III) in aqueous solution. Inorg Chem 49:4156–4166.
   PubMed Web of Science ®Google Scholar
• Morin M, Nenot JC, Lafuma J. 1973. The behavior of 237 Np in the rat. Health Phys 24:311–315.
   PubMed Web of Science ®Google Scholar
• Ni C, Shuh DK, Raymond KN. 2011. Uranyl sequestration: synthesis and structural characterization of uranyl complexes with a tetradentate methylterephthalamide ligand. Chem Commun (Camb) 47:6392–6394.
   PubMed Web of Science ®Google Scholar
• Overvoll PA, Lund W. 1982. Complex formation of uranyl ions with polymainopolycarboxylic acids. Anal Chim Acta 143:153–161.
   Web of Science ®Google Scholar
• Pashalidis I, Kontoghiorghes GJ. 1999. Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-one (deferiprone or l1) with uranium (VI). J Radioanal Nucl Chem 242:181–184.
   Web of Science ®Google Scholar
• Pellmar TC, Rockwell S; Radiological/Nuclear Threat Countermeasures Working Group. 2005. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163:115–123.
   PubMedGoogle Scholar
• Ramounet B, Matton S, Grillon G, Fritsch P. 1998. Early biokinetics of actinides after intravenous administration of soluble forms of Pu(IV), Np(IV) and Np(V). J Alloys Comp 271–273:103–105.
   Web of Science ®Google Scholar
• Stradling GN, Henge-Napoli M.-H, Paquet F, Poncy J.-L, Fritsch P, Taylor DM. 2000. Approaches for experimental evaluation of chelating agents. Radiat Prot Dosim 87:19–27.
   Web of Science ®Google Scholar
• Sturzbecher-Hoehne M, Leung CN, D’Aléo A, Kullgren B, Prigent AL, Shuh DK, Raymond KN, Abergel RJ. 2011. 3,4,3-LI(1,2-HOPO): in vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation. Dalton Trans 40:8340–8346.
   PubMed Web of Science ®Google Scholar
• Szigethy G, Raymond KN. 2011. Hexadentate terephthalamide(bis-hydroxypyridinone) ligands for uranyl chelation: structural and thermodynamic consequences of ligand variation. J Am Chem Soc 133:7942–7956.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Stradling GN, Henge-Napoli MH. 2000. The scientific background to decorporation. Radiat Prot Dosim 87:11–17.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration 2004. Guidance for industry: calcium dtpa and zinc dtpa drug products - submitting a new drug application.
   Google Scholar
• Wood R, Sharp C, Gourmelon P, Le Guen B, Stradling GN, Taylor DM, Henge-Napoli MH. 2000. Decorporation treatment - medical overview. Radiat Prot Dosim 87:51–57.
   Web of Science ®Google Scholar